A significant interaction was detected between CKD status and the effect of SGLT-2 inhibitors on heart failure (RR 0.87, 95% CI 0.75–1.02, p for interaction 0.08): risk reduction with SGLT-2 inhibitors was more important among patients with CKD (Table 3). Here, SLC5A2 is linked to chronic kidney disease.